Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin
Abstract Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells. Rats made hyperglycemic for 8 weeks by streptozotocin, as well as control rats, r...
Guardado en:
Autores principales: | Teruyo Kida, Hidehiro Oku, Sho Osuka, Taeko Horie, Tsunehiko Ikeda |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/957f5abe07324e768c6d21ba5ea03559 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors
por: Y Piña, et al.
Publicado: (2011) -
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
por: Carolina Caro-Vegas, et al.
Publicado: (2019) -
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
por: Morris E Feldman, et al.
Publicado: (2009) -
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury
por: Wang Xiaoping, et al.
Publicado: (2016) -
Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity
por: Lin Hu, et al.
Publicado: (2021)